Fortis Healthcare
Fortis Healthcare scored 71/100 on Panya's 11-signal vendor rubric. Each signal is scored 0 to 100, the methodology is public, and our affiliate posture is flat-fee — never pay-to-rank. Below is the full per-signal breakdown.
- COA on every lot80
- Cold-chain verifiedJCI/NABH-accredited group pharmacy85
- Rx legality (CDSCO)90
- Compound identityIHH-owned, JCI/NABH multi-site85
- Dose accuracyFortis C-DOC Centre of Excellence Diabetes & Endo80
- Endotoxin testing75
- Refund posture60
- Channel clarity36 sites, Vasant Kunj dedicated obesity clinic85
- Support quality80
- Price transparencyno public GLP-1 ladder; consult-led55
- Longitudinal retentionFortis+Healthify digital weight-mgmt program70
Eli Lilly published price ladder ₹3,500/2.5mg vial (~₹14k–17.5k/month). Apollo Pharmacy + hospital prescription. Supply consistent since the March 2025 launch.
Established T2D channel. Off-label weight prescribing common via hospital chains. Most reliable semaglutide route in India.
Oral semaglutide. Apollo Pharmacy stocks. Niche fit.
Wegovy launch is rolling out late-2025/2026. Stock at premium hospitals (Apollo, Fortis, Manipal); supply still ramping.
The 11-signal rubric is public.
Identity, dose accuracy, COA, cold-chain, Rx legality, compound identity, endotoxin testing, refund posture, channel clarity, support quality, price transparency, longitudinal retention. Each scored 0 to 100. Vendors that fail our floor are silently filtered out — they don't appear in our match flow at all.
If Fortis Healthcare wants to dispute or update this score, contact partner@panya.health. Score updates are recorded on this page with a public changelog.
Want a match for your situation?
Take the 2-minute quiz. We'll match you against this and the other vendors in your region — based on your dose, urgency, and budget.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.